Filing Flows › AIM ImmunoTech (AIM) › Q4 2025
AIM ImmunoTech (AIM) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 27, 2026
AIM ImmunoTech (AIM) reported revenue of $21K for the fourth quarter 2025 (Q4 2025), -53% from a year earlier and -19% from the quarter before.
AIM ImmunoTech, Q4 2025: revenue $21K (-53% year over year), net loss $4.2M, operating cash flow −$2.0M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $21K | -19% | -53% |
| Operating profit | −$3.0M | — | — |
| Net earnings | −$4.2M | — | — |
| Operating cash flow | −$2.0M | — | — |
What changed
Revenue was $21K in Q4 2025, down 53% year over year and down 19% from the previous quarter.
Operating costs exceeded revenue by $3.0M, an operating margin of -14057.1%. Total costs fell 50% while revenue fell 53%. The quarter ended with a net loss of $4.2M, wider than the previous quarter's $3.3M loss.
Operating cash flow was −$2.0M. Non-cash charges added back $43K of depreciation and amortization. Working capital and other items added $2.1M.
Questions
What was AIM ImmunoTech's revenue in the fourth quarter 2025?
AIM ImmunoTech (AIM) reported revenue of $21K for the fourth quarter 2025 (Q4 2025), -53% from a year earlier and -19% from the quarter before.
Source: AIM ImmunoTech 10-K on SEC EDGAR.